ArticleFrontiers in public health2025
Prevalence and genotype distribution of human papillomavirus infection among women in Chengdu, China between 2020 and 2024.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Classification and Prioritization of Health Education Needs Among HPV‑Infected Patients in Chengdu: A KANO Model-Based Cross-Sectional Study.Patient preference and adherence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer remains a significant threat to women's health globally. This study aimed to investigate the epidemiological characteristics of human papillomavirus (HPV) infection among women in Chengdu, China, between 2020 and 2024, to provide localized evidence for guiding cervical cancer prevention and control strategies. Methods: A retrospective analysis was conducted using HPV screening data from 51,556 women at Chengdu Women's and Children's Central Hospital (CWCCH) between September 2020 and December 2024. Polymerase chain reaction-gene chip technology (PCR-GCT) was used to genotype 26 HPV types (17 high-risk [HR] and 9 low-risk [LR]). Statistical analyses included the chi-square test and Cochran-Armitage trend analysis. Results: The overall HPV prevalence was 22.03% (11,360/51,556). The infection rate was significantly higher among gynecological outpatients (25.46%) than among participants undergoing routine health screening (13.97%). Single infections predominated (76.47%). The most prevalent HR-HPV genotypes were HPV-52 (3.89%), -16 (3.11%), -58 (2.58%), -51 (2.17%), and -39 (1.54%). A significant increasing trend in prevalence was observed from 2020 (18.70%) to 2024 (25.25%) ( Conclusion: The high and increasing HPV prevalence in Chengdu, along with its bimodal age distribution, seasonal variation, and frequent HR-LR co-infections-highlights the need for targeted interventions. HPV genotyping is recommended for patients with genital warts, particularly prior to procedures such as excision, to identify high-risk co-infections. A dual strategy of "vaccination and standardized screening" should be reinforced, including promoting the 9-valent vaccine (covering HPV-16/52/58) among young women and enhanced systematic screening for middle-aged and older women to control the second infection peak.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.